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EDITORIAL

CKD and Hypertension: Pogo and Pragmatism

I

n this inaugural issue of Advances in Chronic Kidney Disease, 2011, the Guest Editors, Drs. Raymond Townsend
and Domenic Sica, have undertaken the task of compactly
compiling and synthesizing the evidence regarding
hypertension in individuals with CKD. Their team of experts addresses a diverse set of topics that must be considered by practitioners who care for patients with CKD,
those who require no form of renal replacement therapy,
and those who do. Several themes within the theme of
this issue have emerged. First and foremost, hypertension
as a concomitant, global cardiovascular and renal risk
factor remains the overarching principle on which all
therapy must be based. This is followed closely by exposition of how high blood pressure (BP) issues progression
of CKD. In addition, the ‘‘tools of the trade’’ or the antihypertensive agents are reviewed, so as to prevent pitfalls of
pharmacotherapy. Similarly, treatment of hypertension in
populations with special interest to the nephrologist, such
as kidney allograft recipients, individuals with diabetes,
and those undergoing renal replacement therapy by hemodialysis or peritoneal dialysis, has also been included.
Finally, one article has been devoted to newly available
BP-lowering devices that may augment antihypertensive
therapy in those individuals who truly have resistant
hypertension.
Recently released statistics regarding the prevalence,
awareness, and control of high BP reveal improvement
in the latter 2 of these metrics, as evaluated by the 5
National Health and Nutrition Examination Surveys
spanning the period between 1988 and 2008.1 However,
the prevalence of hypertension in the adult population
has continually increased during the 20-year span of
observation. Even more sobering is the thought that
eight-tenths of the one-quarter of a billion persons with
diabetes worldwide have high BP.
However, awareness and control of hypertension
remain suboptimal from the standpoint of a population,
despite many advances in medical therapy of hypertension. The inability to attain target BPs has tremendous
healthcare consequences, and for nephrologists, possibly

the most. Patients with CKD are nearly inextricably
linked to hypertension. Almost 80% of patients with
CKD have hypertension, and the proportion successfully
treated to the American Heart Association and National
Kidney Foundation guideline of ,130/,80 mm Hg is
relatively low. Within the confines of a clinical trial,
only about one-half of African American hypertensive
patients with CKD can attain such BP control.2 Whether
the CKD induced hypertension or so-called benign
hypertension provoked CKD is often indiscernible at patient presentation. In addition, whether MYH9, a gene encoding a myosin heavy chain isotype and expressed in
the glomeruli, is causative, or whether the more recently
described gene APOL1 should be implicated in the pathogenesis of hypertension-related kidney disease, that
is, hypertensive nephrosclerosis, will probably be delineated in the near future.3 However, what must be done
in the meanwhile is self-evident; the elevated BPs of
patients with CKD must be better treated and brought
to a lower range than it had been formerly.
Why does this not occur? The reasons given are
diverse and aplenty. High patient-driven sodium intake,
nonadherence to the medical regimen, which may
include various forms of cultural resistance, adverse
medication events, and the expense of the medications
themselves may foil even the most favorably formulated
antihypertensive regimen. However, another culprit,
often ignored, is ourselves. In the words of Walt Kelly:
‘‘We have met the enemy; and he is us.’’4 Simply, we often
do not achieve the BP goals that we espouse.
With regard to our own treatment of patients with
CKD and hypertension, control rates of BP are highly
variable, and this is dependent on the goal BP of the
treating party. Upper systolic blood pressure limits of
,130 or ,140 mm Hg have been promulgated, and the
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target is modified, by some, in the presence of diabetes.5
Moreover, data are insufficient at present to definitively
state the best upper limit of systolic blood pressure in
nondialysis-dependent patients with CKD. Hopefully,
the ongoing National Institutes of Health-sponsored, randomized, multicenter Systolic Blood Pressure Intervention Trial (SPRINT) will provide a more evidence-based
answer to this conundrum in patients with CKD and
eGFRs of .25 mL/min/1.73 m2 by studying 2 different
levels of BP control: ,140 mm Hg (standard group) versus ,120 mm Hg (treatment group).6 In addition, the
SPRINT-Senior component of this 9-year comparative effectiveness research study will determine best BP management practices in persons of age .75 years. By
comparison, careful observations by Agarwal and colleagues demonstrate that the ideal BP in patients with
ESRD on maintenance hemodialysis may be 20 to 30
mm Hg less than previously conceived.7 Moreover, in
this circumstance, ambulatory BP monitoring and interdialytic BP measurement are the benchmarks. Still, these
procedures have not even been typified in patients without CKD, much less in those with CKD.
Although the primacy of volume in patients with CKD
was established decades ago, the ‘‘dry weight’’ of patients
is not reached in many instances. Insufficient estimation
of ultrafiltration volume, high sodium concentration
dialysate/modeling, and high levels of sodium intake
by the patient conspire to maintain high BPs in such
individuals, and upward ratcheting of existing medications and/or addition of more antihypertensive agents
often proves to be futile. The same lesson applies to
nondialysis-dependent patients with CKD; diuretics
and optimization of the ‘‘dry weight’’ inexplicably
eschewed. Notably, the skin as a reservoir for osmotically
inactive sodium and the magnitude of host lymphatic
networks may play important roles in the pathogenesis
of hypertension in such individuals.8
Thus, together we must pledge as our New Year’s
resolution to treat our patients’ BPs more optimally and
successfully. Certainly, the tools, agents, and knowledge
to treat high BP are available, but only metrics count,
and one of them is the proportion of patients who attain
the target BP. Others would include the number of pills
that a patient takes out of his/her daily allotment, that
is, patient adherence; sodium restriction with attendant
volume contraction and its demonstration by the amount
of sodium in a 24-hour urine collection; the percentage of
proteinuria reduction; and others. Overcoming one’s own
therapeutic inertia must be a mantra this year and in those
to come. Successful treatment of hypertension rarely
occurs solely because of a highly motivated patient or
a highly motivated healthcare provider; it takes 2 to tango.
Consequently, antihypertensive therapy may require
more practice-based ‘‘soft’’ skills, such as greater patient
engagement, than theoretical ones. This, however, does

not imply mitigation of the ‘‘hard’’ skills: medication reconciliation, correction of suboptimal doses of drugs, deletion of inappropriate medications, and use of cost-saving
strategies such as combination therapies (eg, benazepril/
amlodipine), and generic drug substitution. Frequent BP
evaluations and the utilization of ambulatory BP monitoring may be required. The turn-of-the century American
philosophy of Pragmatism is succinctly summarized by
the statement: ‘‘if ‘it’ worked, whatever ‘it’ was is probably
true.’’ Paraphrased, all of the methods that we have concocted to lower BP will be meaningless and ‘‘false’’ if we
cannot effectively apply them to the hypertensive population. As a corollary to the fundamental statement of Pragmatism, when reality (BP targets) changes, the truth, which
is never absolute, will change too. We still have plenty of
work to do before that issue requires resolution, while
we await informative trials regarding optimal methodologies for the treatment of hypertension in CKD, including
the Aliskiren Trial in Type 2 Diabetes Using CardioRenal Endpoints (ALTITUDE)9 and the Veterans Administration NEPHROpathy iN Diabetes (VA NEPHRON-D)
Study.10
Jerry Yee, MD
Editor
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